Neutral
●
Business Wire
●
6 months ago
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that on Wed., March 25, 2026, at 8:30 am Eastern Time, the Company will host a webcast and conference call to present the early clinical results from the Phase 1/2 ascending dose studies of SRP-1001 for facioscapulohumeral muscular dystrophy ty...